Welcome to the SWYAPC website

The information on these pages is intended as a guide only. Whilst we endeavour to keep such information as up to date as possible, we make no claim as to its total accuracy or completeness. Information is liable to change, and such changes may not be mirrored in this site. We do not accept liability for any loss or damage resulting from use of this site or reliance on its content. External links lead to sites and pages over which we have no control, and which we cannot verify for accuracy or content. The inclusion of a link on this website should not be taken as an endorsement of the linked website, nor of the accuracy or quality of the information on such sites.


Ulipristal 5mg – Suspended March 2020 due to MHRA Safety Alert


Updates following the July 2020 Area Prescribing Committee Meeting

Red, Green Specialist Initiation  and Green classifications



Remdesivir – Treatment for SARS-CoV-2 infection

Lorlatinib – Anaplastic lymphoma kinase (ALK)

Sodium zirconium cyclosilicate – Treatment of hyperkalaemia in adult patients

Azithromycin eye drops – Purulent bacterial conjunctivitis

Ceftazidime eye drops – Neisseria conjunctivitis

Natamycin eye drops – Treatment of keratitis due to a mould

Voriconazole eye drops – Candida keratitis

Danazol – Aplastic anaemia

Oxandrolone – Treatment of hypermetabolism in burns patients

Fremanezumab – Migraine


Green Specialist Initiation

Prasterone pessaries – Vulvar & Vaginal atrophy (VVA) in postmenopausal women with moderate to severe symptoms

Colesevelam – Bile acid malabsorption

Fexofenadine oral – Chronic spontaneous urticarial and angioedema (11 years and younger)


Fexofenadine oral – Chronic spontaneous urticarial and angioedema (12 years and over)

Shared Care Guidelines

Phenelezine removed – no longer available





Please refer to the NHS link regarding any information you may need in relation to COVID-19.


Flash Glucose Monitoring – Updated July 2019

We have been working with diabetes specialists in West Yorkshire and Harrogate to update our policies on flash glucose monitoring, following the publication of new guidance from NHS England, and to agree a single policy for all nine clinical commissioning groups.

A Flash Glucose commissioning policy for West Yorkshire and Harrogate has been approved and will start to implement the NHS England guidance regarding “Flash Glucose Monitoring: National Arrangements for Funding of Relevant Diabetes Patients.”  The Diabetes Specialist Teams in local areas will be responsible for assessing whether patients meet the criteria in this guidance, starting flash glucose monitoring and ongoing review.  The continued  supply of the flash glucose monitoring sensors will transfer to the patients GP practice.

There are now available adult and paediatric patient agreement forms for Flash Glucose Monitoring here



Primary Care Antimicrobial Guidelines

On 16 January 2019 the South West Yorkshire Area Prescribing Committee approved local use of the new  NICE/PHE managing common infections guidance.

This supersedes our local primary care guideline. As NICE/PHE have not completed all sections yet, we will continue to use local guidelines for those sections.

NICE/PHE – introduction to guidelines

NICE/PHE table – managing common infections (whole guideline)


Valproate Pregnancy Prevention Programme

The following sections include new information about valproate and pregnancy: Medicines alerts and safety issues; mental health; patient information.


Skin preparations (including emollients)

West Yorkshire Fire & Rescue Service has produced YouTube Videos for the public and patients and one for healthcare professionals warning that skin preparations can increase the risk of a fire developing. The YouTube videos have been added to the following sections of the website for information and discussion:  Medicines Alerts and Safety Issues, Patient Information and Care Homes. There is also information on the Fire Service’s website. The MHRA has issued a press release.